36,628 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Grandfield & Dodd LLC

Grandfield & Dodd LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, HoldingsChannel reports. The firm purchased 36,628 shares of the biopharmaceutical company’s stock, valued at approximately $22,839,000. Regeneron Pharmaceuticals makes up about 1.2% of Grandfield & Dodd LLC’s portfolio, making the stock its 26th biggest holding.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $5,682,636,000. Vanguard Group Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock worth $7,004,838,000 after acquiring an additional 26,884 shares during the last quarter. Dodge & Cox raised its stake in Regeneron Pharmaceuticals by 1.0% in the 4th quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock valued at $3,547,791,000 after acquiring an additional 45,513 shares during the period. Franklin Resources Inc. raised its stake in Regeneron Pharmaceuticals by 4.4% in the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock valued at $1,975,990,000 after acquiring an additional 106,861 shares during the period. Finally, Nuveen LLC lifted its holdings in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after purchasing an additional 835,240 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on REGN. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Citigroup raised their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. TD Cowen upped their price target on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a research note on Thursday, April 23rd. Finally, Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. Sixteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $801.70.

Regeneron Pharmaceuticals Stock Up 0.3%

REGN opened at $805.93 on Tuesday. The stock has a fifty day moving average of $679.69 and a 200-day moving average of $714.24. The company has a market capitalization of $82.98 billion, a P/E ratio of 19.92, a P/E/G ratio of 1.37 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the prior year, the company posted $12.81 earnings per share. Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Insiders Place Their Bets

In related news, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,400 shares of company stock worth $1,090,030 in the last quarter. Corporate insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.